Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 09, 2025 16:16 ET Â | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July…